Text Size
Santen Global

2024 News

Press Release

Notice of Board of Director and Corporate Auditor Nominations
Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
Press Release

IR News

Notice of Board of Director and Corporate Auditor Nominations
Notice of Recording of Impairment Loss and Loss on Valuation of Financial Assets
Santen Announces Share Buyback
Santen Reports Fiscal 2023 Consolidated Performance
Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
IR News

Information

17 Visually Impaired Children Participate in “17th Santen Brasaka Kids’ Camp in Kansai”
Santen selected as "The Sustainability Yearbook Member" by S&P Global in the United States
Website Restoration Notice
Santen Providing Disaster Relief to Communities Impacted by 2024 Noto Peninsula Earthquake
Information
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved